# AVANTECA Partners

> AVANTECA Partners is a VC fund in Basel backing Biotechnology, Health Care and Security. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Basel, Switzerland
- Total investments: 7
- Last investment: Oct 2025
- Lead investor: 29%
- Last updated: Aug 2026
- Website: https://avanteca.com/

Avanteca Partners is an asset management company investing in early-stage Life Science companies.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $805k–$4.6M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 57% |
| Health Care | 3 | 43% |
| Security | 1 | 14% |
| Biopharma | 1 | 14% |
| Public Safety | 1 | 14% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 4 | 57% |
| Series A | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 3 | 43% |
| Spain | 2 | 29% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nanoligent | Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics .Nanoligent mision is to improve the life of patients by designing new medicines that selectively targetthe cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs. | $14.1M | Series A | Oct 06, 2025 |  |
| Onena Medicines | Onena Medicines is a biotechnology company that creates innovative biological medicines to address the large unmet clinical need for breast cancer and other serious orphan illness. | $4.1M | Venture - Series Unknown | Oct 31, 2023 |  |
| Bearmind | Bearmind developing technology for monitoring and real-time analysis of head impact in athletes. | $804.6K | Seed | Jul 24, 2023 |  |
| Bearmind | Bearmind developing technology for monitoring and real-time analysis of head impact in athletes. | $1.4M | Seed | Mar 07, 2023 |  |
| Invasight | Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland. | $4.6M | Seed | Jun 07, 2022 |  |
| Nanoligent | Nanoligent is a biotech company, spin-off of the Universitat Autònoma de Barcelona (UAB) and Institut de Recerca de l'Hospital de la Santa Creu I Sant Pau. We are dedicated to drug design and development of targeted-therapeutic biologics .Nanoligent mision is to improve the life of patients by designing new medicines that selectively targetthe cells affected by disease. With this approach we develope treatments that are more effective and have fewer adverse effects than classical drugs. | $1.1M | Seed | Feb 03, 2022 |  |
| Oncobit | Oncobit enabling personalized cancer care by developing precise and highly sensitive diagnostic and monitoring tests. | $2.5M | Seed | Apr 30, 2021 |  |

7 of 7 investments shown.

## Co-investors
- [Verve Ventures](https://shizune.co/investors/profile/verve-ventures) — VC Fund, 2 deals together
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund, 2 deals together
- [CDTI Innovación's INNVIERTE program](https://shizune.co/investors/profile/cdti-innovaci%C3%B3n-s-innvierte-program) — VC Fund, 1 deal together
- [Clave Capital](https://shizune.co/investors/profile/clave-capital) — VC Fund, 1 deal together
- [GF Group Holding](https://shizune.co/investors/profile/gf-group-holding) — VC Fund, 1 deal together
- [H. Hentsch Asset Management](https://shizune.co/investors/profile/h-hentsch-asset-management) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Biotechnology Investors in Spain](https://shizune.co/investors/biotechnology-investors-spain)
- [Biotechnology VC Funds in Spain](https://shizune.co/investors/biotechnology-vc-funds-spain)
- [Biotech Investors in Spain](https://shizune.co/investors/biotech-investors-spain)
- [Biotech VC Funds in Spain](https://shizune.co/investors/biotech-vc-funds-spain)
- [Medical Device Investors in Spain](https://shizune.co/investors/medical-device-investors-spain)
- [Medical Device VC Funds in Spain](https://shizune.co/investors/medical-device-vc-funds-spain)

## FAQ

### What does AVANTECA Partners invest in?

AVANTECA Partners invests primarily in Biotechnology, Health Care and Security startups, most often at Seed and Series A stage. Most of the 7 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is AVANTECA Partners's check size?

AVANTECA Partners typically joins rounds of $805k–$4.6M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds AVANTECA Partners participates in.

### When did AVANTECA Partners last invest?

The most recent investment recorded for AVANTECA Partners closed in Oct 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co